High-dose Cyclophosphamide is Effective Therapy for Pediatric Severe Aplastic Anemia

Christopher J. Gamper, Clifford M. Takemoto, Allen R. Chen, Heather J. Symons, David M. Loeb, James F. Casella, Amy E. Dezern, Karen E. King, Andrea M. McGonigle, Richard J. Jones, Robert A. Brodsky

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Objective: Use of high-dose cyclophosphamide without hematopoietic stem cell transplant to treat severe aplastic anemia (SAA) has been controversial due to concern for increased infectious toxicity as compared with antithymocyte globulin and cyclosporine A. As children often tolerate dose-intensive therapy better than adults, we sought to perform a detailed retrospective analysis of both treatment response and toxicity in 28 patients younger than 22 years of age treated with 29 courses of high-dose cyclophosphamide as the sole form of immunosuppression. Study Design: Children and adolescents with SAA who lacked an human leukocyte antigen-matched sibling donor were treated with cyclophosphamide 50 mg/kg/d for 4 consecutive days then received daily granulocyte colony stimulating factor until neutrophil recovery, transfusion support, and antimicrobial prophylaxis. Results: Overall survival was 85%, with hematologic response of 79% and complete response of 66%. Cumulative incidences of bacterial infection (86%) and fungal infection (62%) were high but deaths due to infection were rare, as were clonal evolution (1/28), clinically relevant paroxysmal nocturnal (1/28), and relapse (2/28). Conclusions: Response rates and survival following high-dose cyclophosphamide in pediatric patients with SAA exceed those seen in adults and compare favorably to antithymocyte globulin/cyclosporine A with manageable infectious toxicity.

Original languageEnglish (US)
Pages (from-to)627-635
Number of pages9
JournalJournal of Pediatric Hematology/Oncology
Volume38
Issue number8
DOIs
StatePublished - Nov 1 2016
Externally publishedYes

Keywords

  • clinical trials
  • pediatric hematology/oncology
  • severe aplastic anemia

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'High-dose Cyclophosphamide is Effective Therapy for Pediatric Severe Aplastic Anemia'. Together they form a unique fingerprint.

  • Cite this

    Gamper, C. J., Takemoto, C. M., Chen, A. R., Symons, H. J., Loeb, D. M., Casella, J. F., Dezern, A. E., King, K. E., McGonigle, A. M., Jones, R. J., & Brodsky, R. A. (2016). High-dose Cyclophosphamide is Effective Therapy for Pediatric Severe Aplastic Anemia. Journal of Pediatric Hematology/Oncology, 38(8), 627-635. https://doi.org/10.1097/MPH.0000000000000647